Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
Human NK cells can be separated into two functionally distinct subpopulations based on the ability to rapidly respond to IL-2 by adherence to solid surfaces. To determine functions of the NK cell subsets in solid tumor tissues, adherent (A) and nonadherent (NA) NK cells were evaluated for their ability to infiltrate multicellular tumor spheroids in vitro, to kill carcinoma (CA) cell targets in these spheroids, and to mediate antitumor activity in vivo. A-NK cells were less cytolytic than NA-NK cells against CA targets in single cell suspensions or in monolayers. However, A-NK cells showed a significantly better ability than NA-NK cells to infiltrate tumor tissues and kill tumor cells in spheroids of human squamous cell CA of the head and neck or breast CA. Perilesional delivery of human A-NK cells and IL-2 resulted in regression of established human squamous cell carcinoma of the head and neck tumors growing subcutaneously in immunosuppressed nude mice. Similarly, in a xenograft model of human gastric CA metastatic to liver of nude mice, a single intrasplenic injection of A-NK cells in combination with i.p. infusions of IL-2 significantly reduced the number of established hepatic metastases (p < 0.007) and prolonged survival of the mice (p < 0.003). In contrast, NA-NK cells were ineffective in either of the in vivo xenograft tumor models. These findings demonstrate that A-NK cells represent a biologically unique and important subset of NK cells that, in contrast to the rest of NK cells, function as effector cells in solid tumor tissues and, consequently, have a great antitumor therapeutic potential.
Vujanovic
N L
NL
Department of Pathology, University of Pittsburgh School of Medicine, PA.
Yasumura
S
S
Hirabayashi
H
H
Lin
W C
WC
Watkins
S
S
Herberman
R B
RB
Whiteside
T L
TL
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D000818:Animals; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy*; D002448:Cell Adhesion; D002465:Cell Movement; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D006258:Head and Neck Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology* / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology* / Q000637:transplantation; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology* / Q000637:transplantation; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009940:Organoids; D013274:Stomach Neoplasms / Q000473:pathology; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D007376:Interleukin-2